Louise McCullough M.D., Ph.D is a practicing vascular neurologist and professor who is actively engaged in stroke research at the University of Texas Health Science Center in Houston, Texas (UCHC) in the United States. She provides neurological care at Memorial Hermann Hospital, which has a state-of-the-art stroke center and is Co-Director of The Mischer Neuroscience Institute. She holds the Huffington distinguished Chair in Neurology at The McGovern Medical School and participates in teaching, research, medicine, and graduate student mentoring.
Research
Dr. McCullough is perhaps best known for her research identifying gender-based differences in cell death pathways during cerebral ischemia using neuronal nitric oxide synthase (nNOS) and poly ADP ribose polymerase-1 (PARP-1) knockout models which was published in the Journal of Cerebral Blood Flow & Metabolism (2005).[1] This paper was relevant as PARP-inhibiting drugs are currently undergoing clinical trials in a variety of pathologies.[2] Her current research is aggressively investigating the differences in cell death pathways as well as regulation of energy utilization during cerebral ischemia.[3]
Biography
After graduating from the University of Connecticut (Storrs campus), Dr. McCullough obtained her Ph.D from UCONN at Storrs and proceeded to obtain her medical degree from UCONN as well. Her neurology residency and subsequent postdoctoral training were both completed at Johns Hopkins University.
She has grants funded by both the National Institutes of Health (NIH) and the American Heart Association.
References
- ^ McCullough LD, Zeng Z, Blizzard KK, Debchoudhury I, Hurn PD (2005). "Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection". J. Cereb. Blood Flow Metab. 25 (4): 502–12. doi:10.1038/sj.jcbfm.9600059. PMID 15689952.
- ^ "EDDN - Clinical Trials - Cancer Research UK". Archived from the original on 2007-09-28. Retrieved 2008-03-25.
- ^ McCullough LD, Zeng Z, Li H, Landree LE, McFadden J, Ronnett GV (2005). "Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke". J. Biol. Chem. 280 (21): 20493–502. doi:10.1074/jbc.M409985200. PMID 15772080.